


**DIAZEPAM- diazepam tablet**  
**Contract Pharmacy Services-PA**

-----  
**Diazepam**  
**Tablets USP C-IV**  
**Rx only**

**DESCRIPTION**

Diazepam is a benzodiazepine derivative. Chemically, diazepam is 7-Chloro-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one. It is a colorless crystalline compound, and is insoluble in water. The structural formula is represented below:



**C<sub>16</sub>H<sub>13</sub>ClN<sub>2</sub>O** M.W. 284.74

Diazepam Tablets USP 2 mg, 5 mg and 10 mg, for oral administration, contain the following inactive ingredients: anhydrous lactose, magnesium stearate and microcrystalline cellulose.

Diazepam Tablets USP 5 mg also contain D&C Yellow No. 10.

Diazepam Tablets USP 10 mg also contain FD&C Blue No. 1.

**PHARMACOLOGY**

In animals, diazepam appears to act on parts of the limbic system, the thalamus and hypothalamus, and induces calming effects. Diazepam, unlike chlorpromazine and reserpine, has no demonstrable peripheral autonomic blocking action, nor does it produce extrapyramidal side effects; however, animals treated with diazepam do have a transient ataxia at higher doses. Diazepam was found to have transient cardiovascular depressor effects in dogs. Long-term experiments in rats revealed no disturbances of endocrine function.

Oral LD<sub>50</sub> of diazepam is 720 mg/kg in mice and 1240 mg/kg in rats. Intraperitoneal administration of 400 mg/kg to a monkey resulted in death on the sixth day.

**Reproduction Studies**

A series of rat reproduction studies was performed with diazepam in oral doses of 1, 10, 80 and 100 mg/kg. At 100 mg/kg there was a decrease in the number of pregnancies and surviving offspring in these rats. Neonatal survival of rats at doses lower than 100 mg/kg was within normal limits. Several neonates in these rat reproduction studies showed skeletal or other defects. Further studies in rats at doses up to and including 80 mg/kg/day did not reveal teratological effects on the offspring.

In humans, measurable blood levels of diazepam were obtained in maternal and cord blood, indicating

placental transfer of the drug.

## INDICATIONS

Diazepam Tablets USP are indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic.

In acute alcohol withdrawal, diazepam may be useful in the symptomatic relief of acute agitation, tremor, impending or acute delirium tremens and hallucinosis.

Diazepam is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathology (such as inflammation of the muscles or joints, or secondary to trauma); spasticity caused by upper motor neuron disorders (such as cerebral palsy and paraplegia); athetosis; and stiff-man syndrome.

Oral diazepam may be used adjunctively in convulsive disorders, although it has not proved useful as the sole therapy.

The effectiveness of diazepam in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient.

## CONTRAINDICATIONS

Diazepam Tablets USP are contraindicated in patients with a known hypersensitivity to this drug and, because of lack of sufficient clinical experience, in children under 6 months of age. It may be used in patients with open angle glaucoma who are receiving appropriate therapy, but is contraindicated in acute narrow angle glaucoma.

## WARNINGS

Diazepam is not of value in the treatment of psychotic patients and should not be employed in lieu of appropriate treatment. As is true of most preparations containing CNS-acting drugs, patients receiving diazepam should be cautioned against engaging in hazardous occupations requiring complete mental alertness such as operating machinery or driving a motor vehicle.

As with other agents which have anticonvulsant activity, when diazepam is used as an adjunct in treating convulsive disorders, the possibility of an increase in the frequency and/or severity of grand mal seizures may require an increase in the dosage of standard anticonvulsant medication. Abrupt withdrawal of diazepam in such cases may also be associated with a temporary increase in the frequency and/or severity of seizures.

Since diazepam has a central nervous system depressant effect, patients should be advised against the simultaneous ingestion of alcohol and other CNS-depressant drugs during diazepam therapy.

### Usage in Pregnancy

**An increased risk of congenital malformations associated with the use of minor tranquilizers (diazepam, meprobamate and chlordiazepoxide) during the first trimester of pregnancy has been suggested in several studies. Because use of these drugs is rarely a matter of urgency, their use during this period should almost always be avoided. The possibility that a woman of childbearing potential may be pregnant at the time of institution of therapy should be considered. Patients should be advised that if they become pregnant during therapy or intend to become pregnant they should communicate with their physicians about the desirability of discontinuing the drug.**

### Management of Overdosage

Manifestations of diazepam overdose include somnolence, confusion, coma and diminished reflexes. Respiration, pulse and blood pressure should be monitored, as in all cases of drug overdose, although, in general, these effects have been minimal following overdose. General supportive measures should be employed, along with immediate gastric lavage. Intravenous fluids should be administered and an adequate airway maintained. Hypotension may be combated by the use of norepinephrine or metaraminol. Dialysis is of limited value. As with the management of intentional overdose with any drug, it should be borne in mind that multiple agents may have been ingested.

Flumazenil, a specific benzodiazepine receptor antagonist, is indicated for the complete or partial reversal of the sedative effects of benzodiazepines and may be used in situations when an overdose with a benzodiazepine is known or suspected. Prior to the administration of flumazenil, necessary measures should be instituted to secure airway, ventilation, and intravenous access. Flumazenil is intended as an adjunct to, not as a substitute for, proper management of benzodiazepine overdose. Patients treated with flumazenil should be monitored for re-sedation, respiratory depression, and other residual benzodiazepine effects for an appropriate period after treatment. **The prescriber should be aware of a risk of seizure in association with flumazenil treatment, particularly in long-term benzodiazepine users and in cyclic antidepressant overdose.** The complete flumazenil package insert including **CONTRAINDICATIONS, WARNINGS** and **PRECAUTIONS** should be consulted prior to use.

Withdrawal symptoms of the barbiturate type have occurred after the discontinuation of benzodiazepines (see DRUG ABUSE AND DEPENDENCE section).

## **PRECAUTIONS**

If diazepam is to be combined with other psychotropic agents or anticonvulsant drugs, careful consideration should be given to the pharmacology of the agents to be employed — particularly with known compounds which may potentiate the action of diazepam, such as phenothiazines, narcotics, barbiturates, MAO inhibitors and other antidepressants. The usual precautions are indicated for severely depressed patients or those in whom there is any evidence of latent depression; particularly the recognition that suicidal tendencies may be present and protective measures may be necessary. The usual precautions in treating patients with impaired renal or hepatic function should be observed.

In elderly and debilitated patients, it is recommended that the dosage be limited to the smallest effective amount to preclude the development of ataxia or oversedation (2 mg to 2 ½ mg once or twice daily, initially, to be increased gradually as needed and tolerated).

The clearance of diazepam and certain other benzodiazepines can be delayed in association with Tagamet (cimetidine) administration. The clinical significance of this is unclear.

## **Information for Patients**

To assure the safe and effective use of benzodiazepines, patients should be informed that, since benzodiazepines may produce psychological and physical dependence, it is advisable that they consult with their physician before either increasing the dose or abruptly discontinuing this drug.

## **ADVERSE REACTIONS**

Side effects most commonly reported were drowsiness, fatigue and ataxia. Infrequently encountered were confusion, constipation, depression, diplopia, dysarthria, headache, hypotension, incontinence, jaundice, changes in libido, nausea, changes in salivation, skin rash, slurred speech, tremor, urinary retention, vertigo and blurred vision. Paradoxical reactions such as acute hyperexcited states, anxiety, hallucinations, increased muscle spasticity, insomnia, rage, sleep disturbances and stimulation have been reported; should these occur, use of the drug should be discontinued.

Because of isolated reports of neutropenia and jaundice, periodic blood counts and liver function tests are advisable during long-term therapy. Minor changes in EEG patterns, usually low-voltage fast

activity, have been observed in patients during and after diazepam therapy and are of no known significance.

## DRUG ABUSE AND DEPENDENCE

Diazepam tablets are classified by the Drug Enforcement Administration as a schedule IV controlled substance.

Withdrawal symptoms, similar in character to those noted with barbiturates and alcohol (e.g., convulsions, tremor, abdominal and muscle cramps, vomiting and sweating), have occurred following abrupt discontinuance of diazepam. The more severe withdrawal symptoms have usually been limited to those patients who received excessive doses over an extended period of time. Generally milder withdrawal symptoms (e.g., dysphoria and insomnia) have been reported following abrupt discontinuance of benzodiazepines taken continuously at therapeutic levels for several months. Consequently, after extended therapy, abrupt discontinuation should generally be avoided and a gradual dosage tapering schedule followed. Addiction-prone individuals (such as drug addicts or alcoholics) should be under careful surveillance when receiving diazepam or other psychotropic agents because of the predisposition of such patients to habituation and dependence.

## DOSAGE AND ADMINISTRATION

Dosage should be individualized for maximum beneficial effect. While the usual daily dosages given below will meet the needs of most patients, there will be some who may require higher doses. In such cases, dosage should be increased cautiously to avoid adverse effects.

---

### Adults:

*Management of Anxiety Disorders and relief of Symptoms of Anxiety.*

*Symptomatic Relief in Acute Alcohol Withdrawal.*

*Adjunctively for Relief of Skeletal Muscle Spasm.*

*Adjunctively in Convulsive Disorders*

*Geriatric Patients, or in the presence of debilitating disease.*

### Usual Daily Dose

Depending on severity of symptoms —  
2 mg to 10 mg, 2 to 4 times daily  
10 mg, 3 or 4 times during the first 24  
hours, reducing to 5 mg, 3 or 4 times  
daily as needed

2 mg to 10 mg, 3 or 4 times daily

2 mg to 10 mg, 2 to 4 times daily

2 mg to 2 ½ mg, 1 or 2 times daily  
initially; increase gradually as needed  
and tolerated

### Children:

Because of varied responses to CNS-acting drugs, initiate therapy with lowest dose and increase as required. Not for use in children under 6 months.

1 mg to 2 ½ mg, 3 or 4 times daily  
initially; increase gradually as needed  
and tolerated

---

## HOW SUPPLIED

Diazepam Tablets USP 2 mg are scored, round, white tablets imprinted **DAN 5621** and **2** supplied in bottles of 100, 500 and 1000.

Diazepam Tablets USP 5 mg are scored, round, yellow tablets imprinted **DAN 5619** and **5** supplied in bottles of 100, 500 and 1000.

Diazepam Tablets USP 10 mg are scored, round, blue tablets imprinted **DAN 5620** and **10** supplied in bottles of 100, 500 and 1000.

Dispense in tight, light-resistant container with child-resistant closure.

Store at 20°-25°C (68°-77°F). [See USP controlled room temperature.]

**Watson Laboratories, Inc.**

Corona, CA 92880 USA

Repackaged by:

Contract Pharmacy Services-PA

125 Titus Ave Suite 200

Warrington, PA 18976 USA

Original--3/2011--NJW

Updated--08/2011--NJW

**PRINCIPAL DISPLAY PANEL**

**DIAZEPAM**  
10 MG TAB #30

57102040000315  
Rx Only  
CONTROLLED SUBSTANCE  
LOT: SAMPLE  
PILL ID: DAN 5620 10  
EXP: 07/22/12  
WATSON  
Packaged By: Contract Pharmacy Services-PA  
125 Titus Ave, Suite #200, Warrington, PA 18976

Dosage: See package insert for dosage and full prescribing information.  
Store at 20-25°C (68-77°F) (See USP Controlled Room Temperature).  
Each tablet contains: Diazepam USP, 10 mg

CPS NDC: 67046-942-30

FILLED BY \_\_\_\_\_  
CHECKED BY \_\_\_\_\_  
Packaged By: Contract Pharmacy Services-PA  
125 Titus Avenue, Suite #200, Warrington, PA 18976

MED. \_\_\_\_\_  
STRENGTH \_\_\_\_\_  
EXP. DATE \_\_\_\_\_  
MFG. \_\_\_\_\_  
LOT NO. \_\_\_\_\_

**CPs**  
Contract Pharmacy Services

**START**

30 23 15 8  
29 22 14 7  
28 21 13 6  
27 20 12 5  
26 19 11 4  
25 18 10 3  
24 17 9 2  
1

1110.00

WARRINGTON

CAUTION: This package NOT CHILD RESISTANT. Store this and all medications out of reach of children.

**10 mg Blister of 30**

**PRINCIPAL DISPLAY PANEL**

**DIAZEPAM**  
5 MG TAB #30

87105040002310  
Rx Only  
CONTROLLED SUBSTANCE  
LOT - SAMPLE  
PILL ID - DAN 5619 5  
EXP 07/22/12  
WATSON  
Packaged By: Contract Pharmacy Services-PA  
125 Tiltus Ave, Suite #200, Warrington, PA 18976

3 05915 61910 2

Store at 20-25°C (68-77°F) (See USP Controlled Room Temperature)  
Each tablet contains: Diazepam USP, 5 mg

CPS NDC 67046-941-30

FILLED BY \_\_\_\_\_  
CHECKED BY \_\_\_\_\_  
Packaged By: Contract Pharmacy Services-PA  
125 Tiltus Avenue, Suite #200, Warrington, PA 18976

MED. \_\_\_\_\_  
STRENGTH \_\_\_\_\_  
EXP. DATE \_\_\_\_\_  
MFG. \_\_\_\_\_  
LOT NO. \_\_\_\_\_

**Contract Pharmacy Services**

**5 mg Blister of 30**

CAUTION: This package NOT CHILD RESISTANT. Store this and all medications out of reach of children.

**DIAZEPAM**  
diazepam tablet

Product Information			
Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:67046-942(NDC:0591-5620)
Route of Administration	ORAL	DEA Schedule	CIV

Active Ingredient/Active Moiety		
Ingredient Name	Basis of Strength	Strength
Diazepam (UNII: Q3JTX2Q7TU) (Diazepam - UNII:Q3JTX2Q7TU)	Diazepam	10 mg

Inactive Ingredients	
Ingredient Name	Strength
ANHYDROUS LACTOSE (UNII: 3S Y5LH9 PMK)	
magnesium stearate (UNII: 70097M6I30)	
CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D6 1U)	

FD&C BLUE NO. 1 (UNII: HBR47K3TBD)

**Product Characteristics**

<b>Color</b>	BLUE	<b>Score</b>	2 pieces
<b>Shape</b>	ROUND	<b>Size</b>	8mm
<b>Flavor</b>		<b>Imprint Code</b>	DAN;5620;10
<b>Contains</b>			

**Packaging**

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:67046-942-30	30 in 1 BLISTER PACK		

**Marketing Information**

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA071136	03/29/2011	

**DIAZEPAM**

diazepam tablet

**Product Information**

<b>Product Type</b>	HUMAN PRESCRIPTION DRUG	<b>Item Code (Source)</b>	NDC:67046-941(NDC:0591-5619)
<b>Route of Administration</b>	ORAL	<b>DEA Schedule</b>	CIV

**Active Ingredient/Active Moiety**

Ingredient Name	Basis of Strength	Strength
Diazepam (UNII: Q3JTX2Q7TU) (Diazepam - UNII:Q3JTX2Q7TU)	Diazepam	5 mg

**Inactive Ingredients**

Ingredient Name	Strength
ANHYDROUS LACTOSE (UNII: 3SY5LH9PMK)	
magnesium stearate (UNII: 70097M6B0)	
CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U)	
D&C YELLOW NO. 10 (UNII: 35SW5USQ3G)	

**Product Characteristics**

<b>Color</b>	YELLOW	<b>Score</b>	2 pieces
<b>Shape</b>	ROUND	<b>Size</b>	8mm
<b>Flavor</b>		<b>Imprint Code</b>	DAN;5619;5
<b>Contains</b>			

**Packaging**

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:67046-941-30	30 in 1 BLISTER PACK		

**Marketing Information**

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA071135	08/01/2011	

**Labeler** - Contract Pharmacy Services-PA (945429777)

Revised: 8/2011

Contract Pharmacy Services-PA